Galderma Fights Appeal Fee Bid In NYU Oracea Dispute

Law360, New York (August 15, 2013, 3:53 PM ET) -- Galderma Laboratories Inc. on Wednesday hit back at New York University’s bid for it to pay attorneys’ fees stemming from an appeal over a decision invalidating patents behind rosacea treatment Oracea, telling a New York federal judge it shouldn’t have to pay for litigation it didn't instigate.

According to the dermatology drugmaker’s cross-motion for summary judgment, NYU had misinterpreted the agreement that licensed the two NYU patents to Galderma to wrongly argue that it was obligated to pay NYU’s continuing legal fees after the patents were...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required